U.S. Capital Wealth Advisors LLC Acquires Shares of 1,023 Humana Inc. $HUM

Key Points

• U.S. Capital Wealth Advisors LLC purchased 1,023 shares of Humana Inc. in Q2, valued at approximately $250,000.
• Humana's stock is currently priced at $254.72 with a market cap of $30.64 billion and a PE ratio of 19.55.
• The company recently announced a quarterly dividend of $0.885 per share, with a dividend yield of 1.4%.

U.S. Capital Wealth Advisors LLC bought a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,023 shares of the insurance provider's stock, valued at approximately $250,000.

Several other large investors also recently bought and sold shares of HUM. Janney Montgomery Scott LLC purchased a new stake in shares of Humana during the first quarter worth approximately $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Humana by 16.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider's stock worth $300,728,000 after buying an additional 158,528 shares in the last quarter. Focus Partners Wealth raised its position in shares of Humana by 104.2% in the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider's stock valued at $1,701,000 after buying an additional 3,281 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Humana by 2.4% in the first quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock worth $33,256,000 after buying an additional 2,950 shares in the last quarter. Finally, Circle Wealth Management LLC acquired a new position in Humana during the first quarter worth about $425,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE HUM opened at $254.72 on Friday. The stock has a fifty day simple moving average of $271.91 and a 200-day simple moving average of $257.31. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a market cap of $30.64 billion, a PE ratio of 19.55, a P/E/G ratio of 1.50 and a beta of 0.44. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $324.38.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter last year, the firm posted $6.96 earnings per share. The firm's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Equities analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio is currently 27.17%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HUM shares. Wells Fargo & Company lowered their target price on Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. Robert W. Baird lowered their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Truist Financial reduced their price target on Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Piper Sandler cut their price objective on shares of Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Seven analysts have rated the stock with a Buy rating and seventeen have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $289.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.